AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03467867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (IV) will be administered as described in the reporting arm.
Study NCT03467867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab/Hyaluronidase Human
Description: Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
Study NCT04092946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital intervention
Description: Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions.
Study NCT01744184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entonox
Description: Entonox arm
Study NCT01744184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: up to 5mg midazolam as appropriate
Study NCT05178303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-1121(1)
Description: The daily maintenance, SB-1121(1) dose is to take 2 times a day, 1 tablet each time.
Study NCT05178303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-1121(2)
Description: The daily maintenance, SB-1121(2) dose is to take 2 times a day, 1 tablet each time.
Study NCT04264793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Lifestyle Intervention
Description: In addition to usual care in the health center, the intervention included 7 visits with the health center dietitian for individual nutrition counseling, invitation for group nutrition education (5 sessions), individual counseling for physical activity, invitation for a 6-weekly structured group physical activity, DVD on physical activity to perform physical activity at home.
Study NCT04264793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients received usual care including education as part of the diabetes management from their healthcare professionals (physicians and nurses), normally every 2-3 months. Visits with the health center dietitian were arranged as per physician referral.
Study NCT01001481 — intervention group
Intervention type: OTHER
Intervention: Risk status for medication adherence
Description: Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Portal vein flow
Description: Doppler assessment performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-renal flow
Description: Doppler assessment performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic vein flow
Description: Doppler assessment performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary B-lines
Description: Ultrasound assessment of performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dimensions of the inferior vena cava
Description: Ultrasound assessment of performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Left ventricular function
Description: Ultrasound assessment of performed on day 0, 3 and 7.
Study NCT04095143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Right ventricular function
Description: Ultrasound assessment of performed on day 0, 3 and 7.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acknowledgement Racial Injustice AMA
Description: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acknowledgement Racial Injustice AMA
Description: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Study NCT03480191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African American Sender Acknowledgement
Description: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Study NCT03994705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes-11
Description: CAR T-Cells
Study NCT02878720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation
Study NCT02878720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation
Study NCT01389609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg Japanese marketed IR tablet
Description: Immediate release tablet, 4 mg, single dose
Study NCT01389609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg ODT with water
Description: Orally-disintegrating Tablet , 4 mg, single dose with water
Study NCT01389609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg ODT without water
Description: Orally-disintegrating Tablet , 4 mg, single dose without water
Study NCT01694199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency Energy (PRFE)
Description: The intervention is pulsed radiofrequencyenergy (PRFE).
Study NCT03994705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pre-conditioning chemotherapy
Study NCT03994705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pre-conditioning therapy
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Day 1 q2w: 200 mg/m² IV over 30 minutes
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1 q2w: 50 mg/m² IV over 1 hour
Study NCT04447352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: African American Sender Acknowledgement
Description: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Study NCT04375722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 10-Hz
Description: Low frequency alternating current will be applied.
Study NCT04375722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS 40-Hz
Description: High frequency alternating current will be applied.
Study NCT04375722 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS sham
Description: Sham stimulation setting will be applied.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: African American Sender in Informational Videos.
Description: Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: African American Sender in Informational Videos.
Description: Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racial Inequality Highlighted
Description: Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMA Acknowledgement Drug Pricing
Description: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AMA Acknowledgement Drug Pricing
Description: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White Sender in Acknowledgement
Description: Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: White Sender in Acknowledgement
Description: Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White Sender in Informational Videos
Description: Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: White Sender in Informational Videos
Description: Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Racial Inequality Highlighting
Description: In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Study NCT04502056 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo videos
Description: Videos not related to covid-19 will be shown
Study NCT03606122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD P 506 A
Description: PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
Study NCT02160171 — intervention group
Intervention type: DEVICE
Intervention: Algorithm for Neonatal Seizure Recognition
Description: Software system for neonatal seizure detection recognition
Study NCT00951262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a life review program
Description: The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
Study NCT01642602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules.
Study NCT02053545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen & GVHD Prophylaxis
Description: Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF
Study NCT03082716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol Solution
Description: After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
Study NCT03082716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood cardioplegia
Description: After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
Study NCT01942902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Study NCT03798002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro-muscular exercise training Group
Description: Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire
Study NCT03798002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadriceps training program
Description: Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week
Study NCT02529475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric acid
Description: Comparison with patients with Meniere's disease
Study NCT03182140 — intervention group
Intervention type: DRUG
Intervention: Kyleena
Description: Kyleena - intrauterine delivery system containing 19.5 mg LNG
Study NCT01336634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib study treatment was provided as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
Study NCT01336634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study treatment was provided as 0.5 mg and 2 mg tablets. Each tablet contained 0.5 mg or 2 mg of trametinib parent (present as the dimethyl sulfoxide solvate)
Study NCT04157998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intrvenous administration of 10ml normal saline preoperative
Study NCT04157998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 10mg
Description: intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
Study NCT04219098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Butterfly IQ
Description: 10ml of solution with .5cc (or one drop) sterile methylene blue will be injected intra-articularly under ultrasound guidance after a sterile prep. The remaining 20ml will be injected into the periarticular tissues after prosthesis implantation before closure.
Study NCT04219098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The entire volume will be injected into the periarticular tissues after prosthesis implantation before closure.
Study NCT03971708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local anesthetic
Study NCT03971708 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: Local anesthetic
Study NCT01614639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
Study NCT03848364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hip Hop Stroke 2.0
Description: HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
Study NCT02775422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serological Test s for the Virus Chicken Pox Virus
Study NCT04918368 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral scales were used
Description: Women's Health Initiative Sleeplessness Scale (WHISS) and State Anxiety Scale (SAS), were applied.
Study NCT02150837 — intervention group
Intervention type: OTHER
Intervention: 5 & 2 & 2 Plan
Description: Medifast has developed the 5 \& 2 \& 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 \& 2 \& 2 Plan consists of 5 Medifast meal replacements, 2 Lean \& Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and \<30% of calories from fat. The Lean \& Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
Study NCT03378297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets 850 mg x 2 orally